Century Therapeutics Inc (IPSC)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.46-7.59%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Century Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.2M
EPS	—	-0.126
Annual ending 2026-12-31
Revenue	—	4.72M
EPS	—	-0.524
Annual ending 2027-12-31
Revenue	—	3.74M
EPS	—	-0.448

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Submit CNTY-813 IND by Q4 2026	Management aims to submit the CNTY-813 IND by Q4 2026.	Intact	IND submission delayed beyond 2026-Q4	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 distinct disclosures including 2026-Q1 and 2026-Q2 press releases and a 2026-10-02 presentation. Management confirmed IND submission for CNTY-813 remains on track for 4Q 2026 with initial clinical data expected in 2H 2027. Cash position was $217.0M at 2026-Q1 and $197.2M at 2026-Q2, supporting ongoing development. The trajectory is delivering consistent progress toward this milestone. Delivery assessment Oct 24, 2026
Reduce losses and improve EPS	A supporting condition in Century Therapeutics Inc's published investment case. The stated target is EPS loss narrows to better than -$0.40 per share.	Broken	EPS loss worsens beyond -$0.50 per share in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain revenue at approximately $109 million	A primary condition in Century Therapeutics Inc's published investment case. The stated target is Revenue >= $100 million annually.	Under Pressure	Revenue falls below $100 million in any quarter	Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue >= $100 million annually. Target period is not explicitly aligned with this observation. Source published Aug 12, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$3,735,000	3 / 5
2026-07-25	Unavailable	$3,735,000	3 / 5
2026-07-26	Unavailable	$3,735,000	3 / 5
2026-07-27	Unavailable	$3,735,000	3 / 5
2026-07-28	Unavailable	$3,735,000	3 / 5
2026-07-29	Unavailable	$3,735,000	3 / 5
2026-07-30	Unavailable	$0	4 / 5
2026-07-31	Unavailable	$0	4 / 5
2026-08-01	Unavailable	$3,735,000	3 / 5
2026-08-02	Unavailable	$3,735,000	3 / 5
2026-08-03	Unavailable	$3,735,000	3 / 5
2026-08-04	Unavailable	$0	4 / 5
2026-08-05	Unavailable	$0	4 / 5
2026-08-06	Unavailable	$0	4 / 5
2026-08-07	Unavailable	$3,735,000	3 / 5
2026-08-08	Unavailable	$0	4 / 5
2026-08-09	Unavailable	$0	4 / 5
2026-08-10	Unavailable	$0	4 / 5
2026-08-12	Unavailable	$3,735,000	3 / 5
2026-08-13	Unavailable	$0	4 / 5
2026-08-14	Unavailable	$3,735,000	3 / 5
2026-08-15	Unavailable	$3,735,000	3 / 5
2026-08-16	Unavailable	$3,735,000	3 / 5
2026-08-17	Unavailable	$3,735,000	3 / 5
2026-08-18	Unavailable	$3,735,000	3 / 5
2026-08-19	Unavailable	$3,735,000	3 / 5
2026-08-20	Unavailable	$3,735,000	3 / 5
2026-08-21	Unavailable	$3,735,000	3 / 5
2026-08-22	Unavailable	$3,735,000	3 / 5
2026-08-23	Unavailable	$3,735,000	3 / 5
2026-08-24	Unavailable	$3,735,000	3 / 5
2026-08-25	Unavailable	$3,735,000	3 / 5
2026-08-26	Unavailable	$3,735,000	3 / 5
2026-08-27	Unavailable	$3,735,000	3 / 5
2026-08-28	Unavailable	$3,735,000	3 / 5
2026-08-29	Unavailable	$3,735,000	3 / 5
2026-08-30	Unavailable	$3,735,000	3 / 5
2026-08-31	Unavailable	$3,735,000	3 / 5
2026-09-01	Unavailable	$3,735,000	3 / 5
2026-09-02	Unavailable	$3,735,000	3 / 5
2026-09-03	Unavailable	$3,735,000	3 / 5
2026-09-04	Unavailable	$3,735,000	3 / 5
2026-09-05	Unavailable	$3,735,000	3 / 5
2026-09-06	Unavailable	$3,735,000	3 / 5
2026-09-07	Unavailable	$3,735,000	3 / 5
2026-09-08	Unavailable	$3,735,000	3 / 5
2026-09-09	Unavailable	$3,735,000	3 / 5
2026-09-10	Unavailable	$3,735,000	3 / 5
2026-09-11	Unavailable	$3,735,000	3 / 5
2026-09-12	Unavailable	$3,735,000	3 / 5
2026-09-13	Unavailable	$3,735,000	3 / 5
2026-09-14	Unavailable	$3,735,000	3 / 5
2026-09-15	Unavailable	$3,735,000	3 / 5
2026-09-16	Unavailable	$3,735,000	3 / 5
2026-09-17	Unavailable	$3,735,000	3 / 5
2026-09-18	Unavailable	$3,735,000	3 / 5
2026-09-19	Unavailable	$3,735,000	3 / 5
2026-09-20	Unavailable	$3,735,000	3 / 5
2026-09-21	Unavailable	$3,735,000	3 / 5
2026-09-22	Unavailable	$3,735,000	3 / 5
2026-09-23	Unavailable	$3,735,000	3 / 5
2026-09-24	Unavailable	$3,735,000	3 / 5
2026-09-25	Unavailable	$3,735,000	3 / 5
2026-09-26	Unavailable	$3,735,000	3 / 5
2026-09-27	Unavailable	$3,735,000	3 / 5
2026-09-28	Unavailable	$3,735,000	3 / 5
2026-09-29	Unavailable	$3,735,000	3 / 5
2026-09-30	Unavailable	$3,735,000	3 / 5
2026-10-01	Unavailable	$3,735,000	3 / 5
2026-10-02	Unavailable	$3,735,000	3 / 5
2026-10-03	Unavailable	$3,735,000	3 / 5
2026-10-04	Unavailable	$3,735,000	3 / 5
2026-10-05	Unavailable	$3,735,000	3 / 5
2026-10-06	Unavailable	Unavailable	3 / 4
2026-10-07	Unavailable	$3,735,000	3 / 5
2026-10-08	Unavailable	$3,735,000	3 / 5
2026-10-09	Unavailable	$3,735,000	3 / 5
2026-10-10	Unavailable	$3,735,000	3 / 5
2026-10-11	Unavailable	$3,735,000	3 / 5
2026-10-12	Unavailable	$3,735,000	3 / 5
2026-10-13	Unavailable	$3,735,000	3 / 5
2026-10-14	Unavailable	$3,735,000	3 / 5
2026-10-15	Unavailable	$3,735,000	3 / 5
2026-10-16	Unavailable	$3,735,000	3 / 5
2026-10-17	Unavailable	$3,735,000	3 / 5
2026-10-18	Unavailable	$3,735,000	3 / 5
2026-10-19	Unavailable	$3,735,000	3 / 5
2026-10-20	Unavailable	$3,735,000	3 / 5
2026-10-21	Unavailable	$3,735,000	3 / 5
2026-10-22	Unavailable	$3,735,000	3 / 5
2026-10-23	Unavailable	$3,735,000	3 / 5
2026-10-24	Unavailable	$3,735,000	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	1
2026-06-01	4	1
2026-07-01	4	1
2026-08-01	4	1
2026-09-01	4	1
2026-10-01	4	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Submit CNTY-813 IND by Q4 2026Direct metric needs a verified mapping
Reduce losses and improve EPSPublished status: Broken
Maintain revenue at approximately $109 millionPublished status: Under Pressure

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-56.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Century Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology company, not a proven earnings compounder. The long-term thesis is in a watch state: key development milestones remain on track, but recent performance has lagged its industry cohort and the business is loss-making.

What's priced into Century Therapeutics Inc

The valuation evidence points to IPSC being cheap versus peers, while the model has low confidence and shows only a small expectations gap. The pricing signal is tagged as justified, with no fragility warning, but this does not remove the uncertainty around a loss-making business.

What the fundamentals likely do

Near-term results may remain uneven: IPSC had an earnings miss in August after a beat in May, and its near-term miss probability is elevated. Management says CNTY-813 remains on track for an IND submission in 4Q 2026 and CNTY-308 for trial initiation in 2026; cash declined from $217.0 million in 1Q to $197.2 million in 2Q, with runway estimated into 1Q 2029.

What Century Therapeutics Inc hinges on

The multi-year thesis depends on meeting clinical milestones and preserving the stated cash runway. A guidance cut or further weakening in jobs data would add risk, while continued strength among major healthcare peers could support the sector backdrop.